CSPC Innovation Pharmaceutical (300765.SZ) released an announcement regarding the company's holding subsidiary CSPC PHARMA Giant Stone Biological Pharmaceutical Co., Ltd...
According to the Zhitong Finance APP, CSPC Innovation Pharmaceutical (300765.SZ) announced that its holding subsidiary CSPC PHARMA Giant Stone Biological Pharmaceutical Co., Ltd. (referred to as "Giant Stone Biology") recently received the clinical trial approval notice for SYS6005 issued by the National Medical Products Administration, and will soon start clinical trials.
SYS6005 is a monoclonal antibody drug conjugate that can bind to specific receptors on the surface of tumors, enter cells through endocytosis, and release toxins to kill tumor cells. SYS6005 is classified as a first-class biological product for therapeutic use, with the approved indication for advanced tumors, expected to be applicable for the treatment of hematological tumors, ovarian cancer, non-small cell lung cancer, among others. Preclinical studies have shown that SYS6005 has good anti-tumor effects against various cancers, and it is highly likely to demonstrate good therapeutic effects in subsequent clinical trials. Multiple patent applications have been submitted for this product both domestically and internationally.